You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

chidamide

Showing 1 - 25 of 157
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

T-cell Lymphoma Patients After First-line Treatment Failure Trial (SHR2554; Chidamide analog tablets, SHR2554 analog tablets;

Not yet recruiting
  • T-cell Lymphoma Patients After First-line Treatment Failure
  • SHR2554; Chidamide analog tablets
  • SHR2554 analog tablets; Chidamide
  • (no location specified)
Nov 5, 2023

AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • chidamide and azacitidine
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Sep 27, 2023

Peripheral T Cell Lymphoma, Epigenetic Repression Trial in Tianjin (Chidamide, Azacitidine)

Recruiting
  • Peripheral T Cell Lymphoma
  • Epigenetic Repression
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jul 14, 2023

First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting
  • PTCL
  • chidamide
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jul 23, 2023

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Acute Lymphoblastic Leukemia Trial (chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • chidamide
  • +2 more
  • (no location specified)
Oct 19, 2023

Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Cutaneous T-cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 8, 2023

Acute Myeloid Leukemia (Relapsed/Refractory) Trial in Suzhou (Selinexor, Chidamide)

Recruiting
  • Acute Myeloid Leukemia (Relapsed/Refractory)
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 16, 2023

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

Recruiting
  • HR Positive HER2 Negative Advanced Breast Cancer
  • Chidamide
  • Tianjin, China
    天津市肿瘤医院
May 26, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Duvelisib, Chidamide
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023

T Lymphoblastic Leukemia/Lymphoma Trial in Hangzhou (Chidamide)

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • Chidamide
  • Hangzhou, Zhejiang, China
    The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 7, 2023

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide,fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • (no location specified)
Apr 12, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

APL Trial in Shanghai (Chidamide+venetoclax)

Active, not recruiting
  • APL
  • Shanghai, Shanghai, China
    Jiong HU
May 30, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 1, 2023

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • chidamide combined with fulvestrant
  • (no location specified)
Mar 28, 2023

DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Chidamide
  • +3 more
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Apr 10, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma
  • Chidamide
  • Kaohsiung, Taiwan
  • +4 more
Apr 17, 2023

Hepatocellular Carcinoma (HCC) Trial in Taiwan (Chidamide, Regorafenib)

Recruiting
  • Hepatocellular Carcinoma (HCC)
  • Kaohsiung, Taiwan
  • +4 more
Mar 14, 2023

Leukemia, Myeloid, Acute Trial in Chengdu (Chidamide)

Recruiting
  • Leukemia, Myeloid, Acute
  • Chidamide
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Dec 27, 2022

Breast Cancer, Chemo Effect Trial in Beijing (Chidamide)

Recruiting
  • Breast Cancer
  • Chemotherapy Effect
  • Chidamide
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 17, 2023

Triple Negative Breast Cancer Trial in Guangzhou (Chidamide combined with Zimberelimab)

Recruiting
  • Triple Negative Breast Cancer
  • Chidamide combined with Zimberelimab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University, Cancer Center
Nov 20, 2022

Chidamide in Recurrent and Refractory Diffuse Large b

Enrolling by invitation
  • Diffuse Large B-cell Lymphoma
  • Chidamide
  • +2 more
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
Jan 9, 2023

Breast Cancer Trial in Guangzhou (Chidamide Plus Toripalimab Plus Paclitaxel)

Recruiting
  • Breast Cancer
  • Chidamide Plus Toripalimab Plus Paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 19, 2023